Annual report pursuant to Section 13 and 15(d)

Acquisition of Patents and Intangibles - Additional Information (Detail)

v3.20.2
Acquisition of Patents and Intangibles - Additional Information (Detail) - USD ($)
 12 Months Ended
May 31, 2020
May 31, 2019
Oct. 16, 2012
May 31, 2020
May 31, 2019
May 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]            
Asset purchase, cash paid         $ 19,553  
Intangible asset acquired gross $ 3,500,000 $ 3,500,000   $ 3,500,000 3,500,000  
Estimated aggregate future amortization expense in next twelve months 2,000,000     2,000,000    
Estimated aggregate future amortization expense in year two 1,700,000     1,700,000    
Estimated aggregate future amortization expense in year three 1,200,000     1,200,000    
Estimated aggregate future amortization expense in year four 1,000,000     1,000,000    
Estimated aggregate future amortization expense in year five $ 1,000,000     $ 1,000,000    
Acquisition of ProstaGene LLC, value         $ 11,558,000  
Issuance of common stock shares 519,261,580 329,554,763   519,261,580 329,554,763  
Common stock per shares $ 0.001 $ 0.001   $ 0.001 $ 0.001  
ProstaGene, LLC            
Acquired Finite-Lived Intangible Assets [Line Items]            
Acquisition of ProstaGene LLC, value       $ 11,558,000    
Issuance of common stock shares 20,278,000     20,278,000    
Common stock per shares $ 0.57     $ 0.57    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement            
Acquired Finite-Lived Intangible Assets [Line Items]            
Restricted common stock, shares 8,342,000     8,342,000    
Common stock shares restriction period       3 years    
Stock repurchase price, per share       $ 0.001    
ProstaGene, LLC | Investment Advisory, Management and Administrative Service            
Acquired Finite-Lived Intangible Assets [Line Items]            
Investment earned shares 1,620,000     1,620,000    
Patents            
Acquired Finite-Lived Intangible Assets [Line Items]            
Asset purchase, cash paid     $ 3,500,000      
Estimated useful life of acquired asset       10 years    
Amortization expense related to acquired patents $ 4,600,000 $ 4,600,000   $ 2,020,000 $ 1,237,000 $ 350,000